Polycythemia vera in children: a literature review
https://doi.org/10.21682/2311-1267-2024-11-4-71-80
Abstract
Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are clonal myeloid diseases characterized by hyperproduction of differentiated hematopoietic cells. Polycythemia vera (PV) belongs to the group of MPNs and is associated with a high risk of thrombosis, hemorrhagic complications and phenotypic transformation of the disease into myelofibrosis or acute myeloid leukemia. PV is extremely rare among children, first of all, when diagnosing the disease, it is necessary to exclude the secondary cause of erythrocytosis. The incidence of PV is 0.18 per 100,000 people-years the child population. Only half of pediatric patients with PV have symptoms associated with polycythemia. In most children, PV is diagnosed accidentally when an increase in hemoglobin concentration or hematocrit is noted in the full blood count. The mutation JAK2 gene is included in the diagnostic criteria of PV, but its prevalence among children is significantly lower than among adults. In adult patients with PV, the tactics of therapy were determined depending on the risk of complications of the disease: age over 60 years, a history of thrombotic complications. Children rarely have a history of thrombotic events and therefore belong to the low-risk group. Risk factors related to the prognosis and complications of the disease have not been identified for them, data on the results of сytoreductive therapy are also limited, a general algorithm for the treatment of PV in the pediatric population has not been developed, mainly the experience of therapy is extrapolated from adult clinical treatment protocols.
About the Authors
A. V. Bogdanov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
Graduate Student, Pediatric Oncologist of the Hospital for Short-Term Treatment
1 Samory Mashela St., Moscow, 117997
A. V. Pshonkin
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Hematologist, Pediatric Oncologist, Head of the Hospital for Short-Term Treatment
1 Samory Mashela St., Moscow, 117997
References
1. Tefferi A., Vannucchi A.M., Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia. 2021;35(12):3339–51. doi: 10.1038/s41375-021-01401-3. 2. Hofmann I. Myeloproliferative Neoplasms in Children. J Hematop. 2015;8(3):143–57. doi: 10.1007/s12308-015-0256-1.
2. Ishida H., Miyajima Y., Hyakuna N., Hamada S., Sarashina T., Matsumura R., Umeda K., Mitsui T., Fujita N., Tomizawa D., Urayama K.Y., Ishida Y., Taga T., Takagi M., Adachi S., Manabe A., Imamura T., Koh K., Shimada A.; Leukemia/Lymphoma Committee of the Japanese Society of Pediatric Hematology Oncology (JSPHO). Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey. E J Haem. 2020;1(1):86–93. doi: 10.1002/jha2.39.
3. Tefferi A., Rumi E., Finazzi G., Gisslinger H., Vannucchi A.M., Rodeghiero F., Randi M.L., Vaidya R., Cazzola M., Rambaldi A., Gisslinger B., Pieri L., Ruggeri M., Bertozzi I., Sulai N.H., Casetti I., Carobbio A., Jeryczynski G., Larson D.R., Müllauer L., Pardanani A., Thiele J., Passamonti F., Barbui T. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874–81. doi: 10.1038/leu.2013.163.
4. Teofili L., Foà R., Giona F., Larocca L.M. Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients? Haematologica. 2008;93(2):169–72. doi: 10.3324/haematol.12002.
5. Ianotto J.C., Curto-Garcia N., Lauermanova M., Radia D., Kiladjian J.J., Harrison C.N. Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review. Haematologica. 2019;104(8):1580–8. doi: 10.3324/haematol.2018.200832.
6. Sobas M., Kiladjian J.J., Beauverd Y., Curto-Garcia N., Sadjadian P., Shih L.Y., Devos T., Krochmalczyk D., Galli S., Bieniaszewska M., Seferynska I., McMullin M.F., Armatys A., Spalek A., Waclaw J., Zdrenghea M., Legros L., Girodon F., Lewandowski K., Angona Figueras A., Samuelsson J., Abuin Blanco A., Cony-Makhoul P., Collins A., James C., Kusec R., Lauermannova M., Noya M.S., Skowronek M., Szukalski L., Szmigielska-Kaplon A., Wondergem M., Dudchenko I., Gora Tybor J., Laribi K., Kulikowska de Nalecz A., Demory J.L., Le Du K., Zweegman S., Besses Raebel C., Skoda R., Giraudier S., Griesshammer M., Harrison C.N., Ianotto J.C. Realworld study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. Blood Adv. 2022;6(17):5171–83. doi: 10.1182/bloodadvances.2022007201.
7. Giona F., Teofili L., Moleti M.L., Martini M., Palumbo G., Amendola A., Mazzucconi M.G., Testi A.M., Pignoloni P., Orlando S.M., Capodimonti S., Nanni M., Leone G., Larocca L.M., Foà R. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood. 2012;119(10):2219–27. doi: 10.1182/blood-2011-08-371328.
8. Moliterno A.R., Kaizer H., Reeves B.N. JAK2 V617F allele burden in polycythemia vera: burden of proof. Blood. 2023;141(16):1934–42. doi: 10.1182/blood.2022017697.
9. Abu-Zeinah G., Di Giandomenico S., Choi D., Cruz T., Erdos K., Taylor E., Ritchie E.K., Silver R.T., Scandura J.M. Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome. Blood Adv. 2022;6(18):5477–81. doi: 10.1182/bloodadvances.2022007128.
10. Vannucchi A.M., Antonioli E., Guglielmelli P., Longo G., Pancrazzi A., Ponziani V., Bogani C., Ferrini P.R., Rambaldi A., Guerini V., Bosi A., Barbui T.; MPD Research Consortium. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21(9):1952–9. doi: 10.1038/sj.leu.2404854.
11. Mullally A., Poveromo L., Schneider R.K., Al-Shahrour F., Lane S.W., Ebert B.L. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of JAK2V617F-mediated polycythemia vera. Blood. 2012;120(1):166–72. doi: 10.1182/blood-2012-01-402396.
12. Benlabiod C., Dagher T., Marty C., Villeval J.L. Lessons from mouse models of MPN. Int Rev Cell Mol Biol. 2022;366:125–85. doi: 10.1016/bs.ircmb.2021.02.009.
13. Stein B.L., Williams D.M., Wang N.Y., Rogers O., Isaacs M.A., Pemmaraju N., Spivak J.L., Moliterno A.R. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica. 2010;95(7):1090–7. doi: 10.3324/haematol.2009.014407.
14. Cordua S., Kjaer L., Skov V., Pallisgaard N., Hasselbalch H.C., Ellervik C. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood. 2019;134(5):469–79. Blood. 2019;134(14):1195. doi: 10.1182/blood.2019002756.
15. Cordua S., Kjaer L., Skov V., Pallisgaard N., Kefala M., Gjerdrum L.M.R, Hasselbalch H.C., Ellervik C. Early detection of myeloproliferative neoplasms in a Danish general population study. Leukemia. 2021;35(9):2706–9. doi: 10.1038/s41375-021-01159-8.
16. Rodriguez-Meira A., Buck G., Clark S.A., Povinelli B.J., Alcolea V., Louka E., McGowan S., Hamblin A., Sousos N., Barkas N., Giustacchini A., Psaila B., Jacobsen S.E.W., Thongjuea S., Mead A.J. Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing. Mol Cell. 2019;73(6):1292–305.e8. doi: 10.1016/j.molcel.2019.01.009.
17. Fleischman A.G., Aichberger K.J., Luty S.B., Bumm T.G., Petersen C.L., Doratotaj S., Vasudevan K.B., LaTocha D.H., Yang F., Press R.D., Loriaux M.M., Pahl H.L., Silver R.T., Agarwal A., OʼHare T., Druker B.J., Bagby G.C., Deininger M.W. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011;118(24):6392–8. doi: 10.1182/blood-2011-04-348144.
18. Leimkühler N.B., Gleitz H.F.E., Ronghui L., Snoeren I.A.M., Fuchs S.N.R, Nagai J.S., Banjanin B., Lam K.H., Vogl T., Kuppe C., Stalmann U.S.A., Büsche G., Kreipe H., Gütgemann I., Krebs P., Banz Y., Boor P., Tai E.W., Brümmendorf T.H., Koschmieder S., Crysandt M., Bindels E., Kramann R., Costa I.G., Schneider R.K. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell. 2021;28(4):637–52.e8. doi: 10.1016/j.stem.2020.11.004.
19. Luque Paz D., Kralovics R., Skoda R.C. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023;141(16):1909–21. doi: 10.1182/blood.2022017578.
20. Van Egeren D., Escabi J., Nguyen M., Liu S., Reilly C.R., Patel S., Kamaz B., Kalyva M., DeAngelo D.J., Galinsky I., Wadleigh M., Winer E.S., Luskin M.R., Stone R.M., Garcia J.S., Hobbs G.S., Camargo F.D., Michor F., Mullally A., Cortes-Ciriano I., Hormoz S. Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell. 2021;28(3):514–23.e9. doi: 10.1016/j.stem.2021.02.001.
21. Nienhold R., Ashcroft P., Zmajkovic J., Rai S., Rao T.N., Drexler B., Meyer S.C., Lundberg P, Passweg J.R., Leković D., Čokić V., Bonhoeffer S., Skoda R.C. MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. Blood. 2020;136(22):2591–5. doi: 10.1182/blood.2019002943.
22. Busque L., Patel J.P., Figueroa M.E., Vasanthakumar A., Provost S., Hamilou Z., Mollica L., Li J., Viale A., Heguy A., Hassimi M., Socci .N, Bhatt P.K., Gonen M., Mason C.E., Melnick A., Godley L.A., Brennan C.W., Abdel-Wahab O., Levine R.L. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44(11):1179–81. doi: 10.1038/ng.2413.
23. Abu-Zeinah G., Di Giandomenico S., Choi D., Cruz T., Erdos K, Taylor E., Ritchie E.K., Silver R.T., Scandura J.M. Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome. Blood Adv. 2022;6(18):5477–81. doi: 10.1182/bloodadvances.2022007128.
24. Lundberg P., Karow A., Nienhold R., Looser R., Hao-Shen H., Nissen I., Girsberger S., Lehmann T., Passweg J., Stern M., Beisel C., Kralovics R., Skoda R.C. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220–8. doi: 10.1182/blood-2013-11-537167.
25. Nam A.S., Kim K.T., Chaligne R., Izzo F., Ang C., Taylor J., Myers R.M., Abu-Zeinah G., Brand R., Omans N.D., Alonso A., Sheridan C., Mariani M., Dai X., Harrington E., Pastore A., Cubillos-Ruiz J.R., Tam W., Hoffman R., Rabadan R., Scandura J.M., Abdel-Wahab O., Smibert P., Landau D.A. Somatic mutations and cell identity linked by Genotyping of Transcriptomes. Nature. 2019;571(7765):355–60. doi: 10.1038/s41586-019-1367-0.
26. Ortmann C.A., Kent D.G., Nangalia J., Silber Y., Wedge D.C., Grinfeld J., Baxter E.J., Massie C.E., Papaemmanuil E., Menon S., Godfrey A.L., Dimitropoulou D., Guglielmelli P., Bellosillo B., Besses C., Döhner K., Harrison C.N., Vassiliou G.S., Vannucchi A., Campbell P.J., Green A.R. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372(7):601–12. doi: 10.1056/NEJMoa1412098.
27. Kucine N., Al-Kawaaz M., Hajje D., Bussel J., Orazi A. Difficulty distinguishing essential thrombocythaemia from polycythaemia vera in children with JAK2 V617F-positive myeloproliferative neoplasms. Br J Haematol. 2019;185(1):136–9. doi: 10.1111/bjh.15386.
28. El-Sharkawy F., Margolskee E. Pediatric Myeloproliferative Neoplasms. Clin Lab Med. 2021;41(3):529–40. doi: 10.1016/j.cll.2021.04.010.
29. Shimano K.A., Vanderpoel V., Stone H., Resar L., Kucine N. Clinical features associated with thrombotic events in children with myeloproliferative neoplasms. Am J Hematol. 2022;97(9):E353–5. doi: 10.1002/ajh.26646.
30. Kucine N. Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults. Curr Hematol Malig Rep. 2020;15(2):141–8. doi: 10.1007/s11899-020-00571-8.
31. Zhang Y., Zhou Y., Wang Y., Teng G., Li D., Wang Y., Du C, Chen Y., Zhang H., Li Y., Fu L., Chen K., Bai J. Thrombosis among 1537 patients with JAK2V617F-mutated myeloproliferative neoplasms: Risk factors and development of a predictive model. Cancer Med. 2020;9(6):2096–105. doi: 10.1002/cam4.2886.
32. Barraco D., Cerquozzi S., Hanson C.A., Ketterling R.P., Pardanani A., Gangat N., Tefferi A. Prognostic impact of bone marrow fibrosis in polycythemia vera: validation of the IWG-MRT study and additional observations. Blood Cancer J. 2017;7(3):e538. doi: 10.1038/bcj.2017.17.
33. Tam C.S., Nussenzveig R.M., Popat U., Bueso-Ramos C.E., Thomas D.A., Cortes J.A., Champlin R.E., Ciurea S.E., Manshouri T., Pierce S.M., Kantarjian H.M., Verstovsek S. The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms. Blood. 2008;112(5):1628–37. doi: 10.1182/blood-2008-02-138230.
34. Gangat N., Caramazza D., Vaidya R., George G., Begna K., Schwager S., Van Dyke D., Hanson C., Wu W., Pardanani A., Cervantes F., Passamonti F., Tefferi A. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392–7. doi: 10.1200/JCO.2010.32.2446.
35. Dunbar A.J., Rampal R.K., Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020;136(1):61–70. doi: 10.1182/blood.2019000943.
36. Dunbar A.J., Rampal R.K., Levine R. Leukemia secondary to myeloproliferative neoplasms. Blood. 2020;136(1):61–70. doi: 10.1182/blood.2019000943.
37. Harutyunyan A., Klampfl T., Cazzola M., Kralovics R. p53 lesions in leukemic transformation. N Engl J Med. 2011;364(5):488–90. doi: 10.1056/NEJMc1012718.
38. Luque Paz D., Jouanneau-Courville R., Riou J., Ianotto J.C., Boyer F., Chauveau A., Renard M., Chomel J.C., Cayssials E., Gallego-Hernanz M.P., Pastoret C., Murati A., Courtier F., Rousselet M.C., Quintin-Roué I., Cottin L., Orvain C., Thépot S., Chrétien J.M., Delneste Y., Ifrah N., Blanchet O., Hunault-Berger M., Lippert E., Ugo V. Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation. Blood Adv. 2020;4(19):4887–97. doi: 10.1182/bloodadvances.2020002271.
39. Barbui T. How to manage children and young adults with myeloproliferative neoplasms. Leukemia. 2012;26(7):1452–7. doi: 10.1038/leu.2012.12.
40. Nightscales R., McCartney L., Auvrez C., Tao G., Barnard S., Malpas C.B., Perucca P., McIntosh A., Chen Z., Sivathamboo S., Ignatiadis S., Jones S., Adams S., Cook M.J., Kwan P., Velakoulis D., DʼSouza W., Berkovic S.F., OʼBrien T.J. Mortality in patients with psychogenic nonepileptic seizures. Neurology. 2020;95(6):e643ʼ52. doi: 10.1212/WNL.0000000000009855.
41. Mesa R.A., Jamieson C., Bhatia R., Deininger M.W., Fletcher C.D., Gerds A.T., Gojo I., Gotlib J., Gundabolu K., Hobbs G., McMahon B., Mohan S.R., Oh S., Padron E., Papadantonakis N., Pancari P., Podoltsev N., Rampal R., Ranheim E., Reddy V., Rein LAM, Scott B., Snyder D.S., Stein B.L., Talpaz M., Verstovsek S., Wadleigh M., Wang E.S., Bergman M.A., Gregory K.M., Sundar H. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Canc Netw. 2017;15(10):1193–207. doi: 10.6004/jnccn.2017.0157.
42. Kucine N., Bergmann S., Krichevsky S., Jones D., Rytting M., Jain J., Bennett C.M., Resar L.M.S, Mascarenhas J., Verstovsek S., Hoffman R. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia. Pediatr Blood Cancer. 2021;68(3):e28888. doi: 10.1002/pbc.28888.
43. Kiladjian J.J., Klade C., Georgiev P., Krochmalczyk D., Gercheva-Kyuchukova L., Egyed M., Dulicek P., Illes A., Pylypenko H., Sivcheva L., Mayer J., Yablokova V., Krejcy K., Empson V., Hasselbalch H.C., Kralovics R., Gisslinger H.; PROUD-PV Study Group. Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. Leukemia. 2022;36(5):1408–11. doi: 10.1038/s41375-022-01528-x.
44. Verger E., Soret-Dulphy J., Maslah N., Roy L., Rey J., Ghrieb Z., Kralovics R., Gisslinger H., Grohmann-Izay B., Klade C., Chomienne C., Giraudier S., Cassinat B., Kiladjian J.J. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J. 2018;8(10):94. doi: 10.1038/s41408-018-0133-0.
45. De Oliveira R.D., Soret-Dulphy J., Zhao L.P., Marcault C., Gauthier N., Verger E., Kiladjian J.J. Interferon-alpha (IFN) therapy discontinuation is feasible in myeloproliferative neoplasm (MPN) patients with complete hematological remission. Blood. 2020;136:35–6. doi: 10.1182/blood-2020-141223.
46. Kiladjian J.J., Zachee P., Hino M., Pane F., Masszi T., Harrison C.N., Mesa R., Miller C.B., Passamonti F., Durrant S., Griesshammer M., Kirito K., Besses C., Moiraghi B., Rumi E., Rosti V., Blau I.W., Francillard N., Dong T., Wroclawska M., Vannucchi A.M., Verstovsek S. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020;7(3):e226–37. doi: 10.1016/S2352-3026(19)30207-8.
47. Harrison C.N., Nangalia J., Boucher R., Jackson A., Yap .C, OʼSullivan J., Fox S., Ailts I., Dueck A.C., Geyer H.L., Mesa R.A., Dunn W.G., Nadezhdin E., Curto-Garcia N., Green A., Wilkins B., Coppell J., Laurie J., Garg M., Ewing J., Knapper S., Crowe J., Chen F., Koutsavlis I., Godfrey A., Arami S., Drummond M., Byrne J., Clark F., Mead-Harvey C., Baxter E.J., McMullin M.F., Mead A.J. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. J Clin Oncol. 2023;41(19):3534–44. doi: 10.1200/JCO.22.01935.
Review
For citations:
Bogdanov A.V., Pshonkin A.V. Polycythemia vera in children: a literature review. Russian Journal of Pediatric Hematology and Oncology. 2024;11(4):71-80. (In Russ.) https://doi.org/10.21682/2311-1267-2024-11-4-71-80
Views:
154
Email this article 